OrbiMed Advisors PMVP Position
Active8-Fund ConvergenceOrbiMed Advisors trimmed their position in PMV Pharmaceuticals, Inc. (PMVP) in Q4 2025, holding $6.2M worth of shares across 4,975,291 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
PMVP is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for rezatapopt in 121 days (Aug 15, 2026), making the timing of OrbiMed's position particularly relevant.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Full company profile →Short Interest
3.3%
1.3 days to cover
OrbiMed Advisors PMVP Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 4,975,291 | -1,000,000 | $6.2M |
| Q3 2025 | Decreased | 5,975,291 | -500,000 | $8.4M |
| Q2 2025 | Held | 6,475,291 | — | $6.9M |
| Q1 2025 | Held | 6,475,291 | — | $7.1M |
| Q4 2024 | Held | 6,475,291 | — | $9.8M |
| Q3 2024 | Held | 6,475,291 | — | $9.6M |
| Q2 2024 | Held | 6,475,291 | — | $10.5M |
| Q1 2024 | Held | 6,475,291 | — | $11.0M |
| Q4 2023 | Decreased | 6,475,291 | -87,786 | $20.1M |
| Q3 2023 | Held | 6,563,077 | — | $40.3M |
| Q2 2023 | Held | 6,563,077 | — | $41.1M |
| Q1 2023 | New | 6,563,077 | +6,563,077 | $31.3M |
Frequently Asked Questions
Does OrbiMed Advisors own PMVP?
Yes. As of Q4 2025, OrbiMed Advisors holds 4,975,291 shares of PMV Pharmaceuticals, Inc. (PMVP) valued at $6.2M. This data comes from their SEC 13F filing.
How many hedge funds own PMVP?
8 specialist biotech hedge funds currently hold PMVP, including Boxer Capital, Avoro Capital Advisors, RTW Investments and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy PMVP?
OrbiMed Advisors's position in PMVP was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's PMVP position increasing or decreasing?
OrbiMed Advisors trimmed their PMVP position in the most recent quarter, reducing by 1,000,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PMVPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →